Becton Dickinson and Company (BDX) - Net Assets
Based on the latest financial reports, Becton Dickinson and Company (BDX) has net assets worth $25.28 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($54.84 Billion) and total liabilities ($29.56 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Becton Dickinson and Company to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.28 Billion |
| % of Total Assets | 46.1% |
| Annual Growth Rate | 9.47% |
| 5-Year Change | 7.23% |
| 10-Year Change | 232.58% |
| Growth Volatility | 16.62 |
Becton Dickinson and Company - Net Assets Trend (1985–2025)
This chart illustrates how Becton Dickinson and Company's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Becton Dickinson and Company for the complete picture of this company's asset base.
Annual Net Assets for Becton Dickinson and Company (1985–2025)
The table below shows the annual net assets of Becton Dickinson and Company from 1985 to 2025. For live valuation and market cap data, see BDX market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $25.39 Billion | -1.93% |
| 2024-09-30 | $25.89 Billion | +0.36% |
| 2023-09-30 | $25.80 Billion | +2.04% |
| 2022-09-30 | $25.28 Billion | +6.78% |
| 2021-09-30 | $23.68 Billion | -0.37% |
| 2020-09-30 | $23.77 Billion | +12.32% |
| 2019-09-30 | $21.16 Billion | +0.79% |
| 2018-09-30 | $20.99 Billion | +62.14% |
| 2017-09-30 | $12.95 Billion | +69.61% |
| 2016-09-30 | $7.63 Billion | +1.69% |
| 2015-09-30 | $7.51 Billion | +48.57% |
| 2014-09-30 | $5.05 Billion | +0.22% |
| 2013-09-30 | $5.04 Billion | +21.91% |
| 2012-09-30 | $4.14 Billion | -14.34% |
| 2011-09-30 | $4.83 Billion | -11.16% |
| 2010-09-30 | $5.43 Billion | +5.68% |
| 2009-09-30 | $5.14 Billion | +4.20% |
| 2008-09-30 | $4.94 Billion | +13.15% |
| 2007-09-30 | $4.36 Billion | +13.71% |
| 2006-09-30 | $3.84 Billion | +19.02% |
| 2005-09-30 | $3.22 Billion | +5.06% |
| 2004-09-30 | $3.07 Billion | +5.90% |
| 2003-09-30 | $2.90 Billion | +16.44% |
| 2002-09-30 | $2.49 Billion | +6.84% |
| 2001-09-30 | $2.33 Billion | +19.06% |
| 2000-09-30 | $1.96 Billion | +10.59% |
| 1999-09-30 | $1.77 Billion | +9.60% |
| 1998-09-30 | $1.61 Billion | +16.49% |
| 1997-09-30 | $1.39 Billion | +4.54% |
| 1996-09-30 | $1.33 Billion | -5.23% |
| 1995-09-30 | $1.40 Billion | -5.62% |
| 1994-09-30 | $1.48 Billion | +1.70% |
| 1993-09-30 | $1.46 Billion | -8.65% |
| 1992-09-30 | $1.59 Billion | +16.95% |
| 1991-09-30 | $1.36 Billion | +10.55% |
| 1990-09-30 | $1.23 Billion | +15.13% |
| 1989-09-30 | $1.07 Billion | +11.64% |
| 1988-09-30 | $959.80 Million | +11.44% |
| 1987-09-30 | $861.30 Million | +7.14% |
| 1986-09-30 | $803.90 Million | +18.03% |
| 1985-09-30 | $681.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Becton Dickinson and Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2624.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $16.62 Billion | 65.47% |
| Common Stock | $371.00 Million | 1.46% |
| Other Comprehensive Income | $-1.87 Billion | -7.37% |
| Other Components | $10.27 Billion | 40.44% |
| Total Equity | $25.39 Billion | 100.00% |
Becton Dickinson and Company Competitors by Market Cap
The table below lists competitors of Becton Dickinson and Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Microchip Technology Inc
NASDAQ:MCHP
|
$42.51 Billion |
|
Danone SA
F:BSND
|
$42.57 Billion |
|
Coinbase Global Inc
NASDAQ:COIN
|
$42.66 Billion |
|
ITC Limited
NSE:ITC
|
$42.67 Billion |
|
Polski Koncern Naftowy ORLEN SA
WAR:PKN
|
$42.47 Billion |
|
Bank Central Asia Tbk
JK:BBCA
|
$42.25 Billion |
|
Coca-Cola European Partners PLC
NASDAQ:CCEP
|
$42.25 Billion |
|
American International Group Inc
NYSE:AIG
|
$42.23 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Becton Dickinson and Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 25,889,000,000 to 25,390,000,000, a change of -499,000,000 (-1.9%).
- Net income of 1,678,000,000 contributed positively to equity growth.
- Dividend payments of 1,196,000,000 reduced retained earnings.
- Share repurchases of 1,000,000,000 reduced equity.
- Other comprehensive income decreased equity by 138,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.68 Billion | +6.61% |
| Dividends Paid | $1.20 Billion | -4.71% |
| Share Repurchases | $1.00 Billion | -3.94% |
| Other Comprehensive Income | $-138.00 Million | -0.54% |
| Other Changes | $157.00 Million | +0.62% |
| Total Change | $- | -1.93% |
Book Value vs Market Value Analysis
This analysis compares Becton Dickinson and Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 71.45x to 1.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-09-30 | $2.09 | $149.31 | x |
| 1986-09-30 | $2.37 | $149.31 | x |
| 1987-09-30 | $2.61 | $149.31 | x |
| 1988-09-30 | $3.02 | $149.31 | x |
| 1989-09-30 | $3.43 | $149.31 | x |
| 1990-09-30 | $4.03 | $149.31 | x |
| 1991-09-30 | $4.44 | $149.31 | x |
| 1992-09-30 | $5.23 | $149.31 | x |
| 1993-09-30 | $4.65 | $149.31 | x |
| 1994-09-30 | $5.03 | $149.31 | x |
| 1995-09-30 | $5.06 | $149.31 | x |
| 1996-09-30 | $5.02 | $149.31 | x |
| 1997-09-30 | $5.36 | $149.31 | x |
| 1998-09-30 | $6.22 | $149.31 | x |
| 1999-09-30 | $6.75 | $149.31 | x |
| 2000-09-30 | $7.47 | $149.31 | x |
| 2001-09-30 | $8.70 | $149.31 | x |
| 2002-09-30 | $9.33 | $149.31 | x |
| 2003-09-30 | $11.01 | $149.31 | x |
| 2004-09-30 | $11.67 | $149.31 | x |
| 2005-09-30 | $12.60 | $149.31 | x |
| 2006-09-30 | $14.94 | $149.31 | x |
| 2007-09-30 | $17.10 | $149.31 | x |
| 2008-09-30 | $19.53 | $149.31 | x |
| 2009-09-30 | $20.84 | $149.31 | x |
| 2010-09-30 | $22.63 | $149.31 | x |
| 2011-09-30 | $21.34 | $149.31 | x |
| 2012-09-30 | $19.77 | $149.31 | x |
| 2013-09-30 | $25.31 | $149.31 | x |
| 2014-09-30 | $25.56 | $149.31 | x |
| 2015-09-30 | $34.53 | $149.31 | x |
| 2016-09-30 | $35.09 | $149.31 | x |
| 2017-09-30 | $57.91 | $149.31 | x |
| 2018-09-30 | $79.34 | $149.31 | x |
| 2019-09-30 | $76.72 | $149.31 | x |
| 2020-09-30 | $84.15 | $149.31 | x |
| 2021-09-30 | $81.06 | $149.31 | x |
| 2022-09-30 | $87.98 | $149.31 | x |
| 2023-09-30 | $89.45 | $149.31 | x |
| 2024-09-30 | $88.96 | $149.31 | x |
| 2025-09-30 | $88.43 | $149.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Becton Dickinson and Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.61%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.68%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.18x
- Recent ROE (6.61%) is below the historical average (15.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 12.92% | 7.69% | 0.92x | 1.82x | $19.89 Million |
| 1986 | 13.92% | 8.53% | 0.78x | 2.10x | $31.51 Million |
| 1987 | 16.46% | 8.96% | 0.84x | 2.20x | $55.67 Million |
| 1988 | 16.88% | 9.48% | 0.83x | 2.15x | $66.02 Million |
| 1989 | 15.76% | 9.32% | 0.80x | 2.12x | $61.75 Million |
| 1990 | 14.78% | 9.06% | 0.78x | 2.10x | $58.94 Million |
| 1991 | 13.92% | 8.74% | 0.78x | 2.04x | $53.42 Million |
| 1992 | 12.59% | 8.49% | 0.74x | 1.99x | $41.31 Million |
| 1993 | 4.92% | 2.91% | 0.80x | 2.12x | $-73.99 Million |
| 1994 | 15.33% | 8.88% | 0.81x | 2.13x | $79.03 Million |
| 1995 | 18.00% | 9.28% | 0.90x | 2.14x | $111.86 Million |
| 1996 | 21.40% | 10.24% | 0.96x | 2.18x | $151.08 Million |
| 1997 | 21.66% | 10.68% | 0.91x | 2.22x | $161.56 Million |
| 1998 | 14.66% | 7.59% | 0.81x | 2.38x | $75.22 Million |
| 1999 | 15.59% | 8.07% | 0.77x | 2.51x | $98.83 Million |
| 2000 | 20.09% | 10.86% | 0.80x | 2.30x | $197.30 Million |
| 2001 | 17.25% | 10.70% | 0.78x | 2.06x | $168.78 Million |
| 2002 | 19.29% | 12.12% | 0.79x | 2.03x | $231.18 Million |
| 2003 | 18.88% | 12.26% | 0.80x | 1.92x | $257.36 Million |
| 2004 | 15.24% | 9.47% | 0.86x | 1.88x | $160.62 Million |
| 2005 | 21.99% | 13.34% | 0.89x | 1.85x | $393.87 Million |
| 2006 | 19.61% | 13.11% | 0.84x | 1.78x | $368.66 Million |
| 2007 | 20.40% | 13.99% | 0.87x | 1.68x | $453.84 Million |
| 2008 | 22.83% | 15.93% | 0.89x | 1.60x | $633.44 Million |
| 2009 | 23.95% | 17.63% | 0.75x | 1.81x | $717.33 Million |
| 2010 | 24.24% | 18.49% | 0.74x | 1.78x | $774.15 Million |
| 2011 | 26.32% | 16.76% | 0.73x | 2.16x | $788.18 Million |
| 2012 | 28.29% | 15.18% | 0.68x | 2.75x | $756.40 Million |
| 2013 | 25.64% | 16.05% | 0.66x | 2.41x | $788.80 Million |
| 2014 | 23.45% | 14.03% | 0.68x | 2.46x | $679.70 Million |
| 2015 | 9.70% | 6.76% | 0.38x | 3.74x | $-21.50 Million |
| 2016 | 12.78% | 7.82% | 0.49x | 3.35x | $212.60 Million |
| 2017 | 8.50% | 9.10% | 0.32x | 2.91x | $-194.80 Million |
| 2018 | 1.48% | 1.95% | 0.30x | 2.57x | $-1.79 Billion |
| 2019 | 5.85% | 7.13% | 0.33x | 2.46x | $-875.20 Million |
| 2020 | 3.68% | 5.44% | 0.30x | 2.27x | $-1.50 Billion |
| 2021 | 8.84% | 10.94% | 0.36x | 2.28x | $-275.70 Million |
| 2022 | 7.04% | 9.43% | 0.36x | 2.09x | $-749.20 Million |
| 2023 | 5.75% | 7.66% | 0.37x | 2.05x | $-1.10 Billion |
| 2024 | 6.59% | 8.45% | 0.35x | 2.21x | $-883.90 Million |
| 2025 | 6.61% | 7.68% | 0.39x | 2.18x | $-861.00 Million |
Industry Comparison
This section compares Becton Dickinson and Company's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $870,414,600
- Average return on equity (ROE) among peers: -28.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Becton Dickinson and Company (BDX) | $25.28 Billion | 12.92% | 1.17x | $42.47 Billion |
| Akoya Biosciences Inc (AKYA) | $18.57 Million | -89.96% | 3.18x | $64.44 Million |
| Align Technology Inc (ALGN) | $99.40 Million | -98.06% | 0.19x | $12.66 Billion |
| AngioDynamics Inc (ANGO) | $424.49 Million | -6.25% | 0.30x | $444.32 Million |
| AptarGroup Inc (ATR) | $1.28 Billion | 13.56% | 0.59x | $7.66 Billion |
| AtriCure Inc (ATRC) | $483.76 Million | 10.38% | 0.27x | $1.44 Billion |
| Avinger Inc (AVGR) | $-143.87 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $62.68 Million | -121.71% | 0.29x | $156.14 Million |
| Avantor Inc (AVTR) | $-3.05 Billion | 0.00% | 0.00x | $5.43 Billion |
| Azenta Inc (AZTA) | $415.04 Million | 3.07% | 0.24x | $1.04 Billion |
| Baxter International Inc (BAX) | $9.12 Billion | 6.60% | 0.88x | $8.85 Billion |
About Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segme… Read more